Hospital Universitario La Paz-ko ikertzaileekin lankidetzan egindako argitalpenak (14)

2024

  1. COVID-19 Outcomes in Patients with Hematologic Malignancies in the Era of COVID-19 Vaccination and the Omicron Variant

    Cancers, Vol. 16, Núm. 2

  2. Rationale and design of RESILIENCE: A prospective randomized clinical trial evaluating remote ischaemic conditioning for the prevention of anthracycline cardiotoxicity

    European Journal of Heart Failure

2023

  1. COVID-19 Severity and Survival over Time in Patients with Hematologic Malignancies: A Population-Based Registry Study

    Cancers, Vol. 15, Núm. 5

2020

  1. Early detection of lysosomal diseases by screening of cases of idiopathic splenomegaly and/or thrombocytopenia with a next-generation sequencing gene panel

    JIMD Reports, Vol. 51, Núm. 1, pp. 53-61

2019

  1. Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group)

    Annals of Oncology, Vol. 30, Núm. 4, pp. 612-620

2018

  1. Intestinal perforation secondary to intestinal diffuse large b-cell lymphoma in a patient with coeliac disease

    Gastroenterologia y Hepatologia, Vol. 41, Núm. 8, pp. 503-504

2017

  1. Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study

    PLoS ONE, Vol. 12, Núm. 9

2014

  1. Emergence and long-lasting persistence of linezolid-resistant enterococcus faecium-ST117 in an oncohematologic patient after a nine-day course of linezolid

    Microbial Drug Resistance, Vol. 20, Núm. 1, pp. 17-21

  2. GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: Do we still need alkylators?

    Blood, Vol. 124, Núm. 12, pp. 1887-1893

  3. Phase IV open-label study of the efficacy and safety of deferasirox after allogeneic stem cell transplantation

    Haematologica, Vol. 99, Núm. 10, pp. 1632-1637

2012

  1. Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial

    Blood, Vol. 120, Núm. 13, pp. 2581-2588

2011

  1. Mortality risk factors in patients with zygomycosis: A retrospective and multicentre study of 25

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 29, Núm. 4, pp. 263-268

2004

  1. Chromosome 21 tandem repetition and AML1 (RUNX1) gene amplification

    Cancer Genetics and Cytogenetics, Vol. 149, Núm. 1, pp. 11-16

1998

  1. Normal and clonal B lineage cells can be distinguished by their differential expression of B cell antigens and adhesion molecules in peripheral blood from multiple myeloma (MM) patients diagnostic and clinical implications

    Clinical and Experimental Immunology, Vol. 112, Núm. 3, pp. 410-418